Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerogenic Fibroblasts in Refractory Multiple Sclerosis
NCT05080270Phase 1Completed
- Sponsor
- FibroBiologics
- Start
- Sep 2020
- Primary completion
- Jun 2021
- Modality
- Tissue Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tolerogenic fibroblasts in multiple sclerosis (MS), sponsored by FibroBiologics. Primary endpoints: Adverse Events at 4 hours, Complete Blood Count at week 16 and 2 more. Started Sep 2020; status: completed.
02
Drugs
tolerogenic fibroblasts
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05080270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080270.